Cara Therapeutics' Stock Buoyed By Positive Korsuva Data For Post-Op Pain

Cara Therapeutics will discuss its options with regulators after positive top-line data from adaptive Phase II/III trial of its Korsuva drug in patients undergoing abdominal surgeries met its prime endpoint and sent the biotech's stock higher.

Laparoscopic equipment
Phase II/III Korsuva trial met its primary endpoint in patients undergoing abdominal surgeries • Source: Shutterstock

The market for non-addictive analgesics was in the minds of investors who sent shares in Cara Therapeutics Inc. sharply higher this week on news its investigational drug Korsuva (CR845/difelikefalin) in a Phase II/III trial met its primary endpoint by showing statistically significant reduction in pain intensity in patients undergoing abdominal surgery.

The randomized, placebo-controlled study involved 228 patients who underwent ventral hernia surgery and 216 patients who had a hysterectomy. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.